Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic agent and ophthalmologic drug

A preparation and inhibitor technology, applied in the field of ophthalmic preparations and ophthalmic medicines, can solve problems such as symptomatic therapy of unknown heaviness

Inactive Publication Date: 2019-06-04
LION CORP
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a countermeasure, treatment of the disease that is the cause can be mentioned, but until now, there is no symptomatic treatment that is effective for the feeling of heaviness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic agent and ophthalmologic drug
  • Ophthalmic agent and ophthalmologic drug
  • Ophthalmic agent and ophthalmologic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0167] Hereinafter, the present invention will be described in more detail by way of examples. The following examples are intended to illustrate the invention, but not to limit it.

[0168] [Viscosity (mPa·s)]

[0169] The ophthalmic preparations produced in Examples and Comparative Examples were subjected to viscosity measurement at 20° C. using an E-type viscometer (“VISCONIC ELD-R”, manufactured by Tokyo Keiki Co., Ltd.).

[0170] [Evaluation of subjective symptoms]

[0171] People who have symptoms of dry eyes and belong to the diagnostic criteria of dry eye syndrome (New Ophthalmology 24 (2): 181-184, 2007) are more likely to have "eye gum", "heavy feeling", "eye fatigue (eye fatigue) )", "blurred vision", "congestion", "photophobia", "eye itching" and 7 panelists were tested. Two weeks were set as the pre-observation period, and during the pre-observation period, eye drops (artificial tears "artificial tear eye drops (manufactured by Senju Pharmaceutical Co., Ltd.)") ...

Embodiment 1

[0188] After dissolving 0.05 g of d-α-tocopheryl acetate (manufactured by Riken Vitamin Co., Ltd., "Riken Acetate α") in purified water through 1.0 g of polyoxyethylene (200) polyoxypropylene (70) diol, Hypromellose 0.15 g (manufactured by Shin-Etsu Chemical Co., Ltd., "METOLOSE 60SH-4000"; weight average molecular weight about 300,000) and sodium chloride 0.9 g were dissolved in purified water to prepare an ophthalmic preparation (test drug) 100mL. The produced ophthalmic preparation had a viscosity of 7 mPa·s at 20°C and a pH of 7.1 at 20°C. Using the produced ophthalmic preparations, evaluation of subjective symptoms was performed. The results are shown in Tables 2 and 4.

Embodiment 2

[0190] 0.05 g of d-α-tocopheryl acetate (manufactured by Riken Vitamin Co., Ltd., "Riken Acetate α") and retinyl palmitate 50,000 I.U. (manufactured by Roche Vitamin Japan Co., Ltd., "palmitic acid Retinol") was dissolved in purified water with 1.0 g of polyoxyethylene (200) polyoxypropylene (70) diol, and 0.15 g of hypromellose (manufactured by Shin-Etsu Chemical Co., Ltd., ) and 0.9 g of sodium chloride were dissolved in purified water to prepare 100 mL of an ophthalmic preparation (test drug). The produced ophthalmic preparation had a viscosity of 7 mPa·s at 20°C and a pH of 7.1 at 20°C. Using the produced ophthalmic preparations, evaluation of subjective symptoms was performed. The results are described in Tables 2-5.

[0191] 【Table 2】

[0192]

[0193] From the results of Comparative Example 1, it can be seen that the ophthalmic preparation containing no active ingredient did not produce the desired efficacy at all. In addition, from the results of Comparative Ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to View More

Abstract

The present invention addresses the problem of providing an ophthalmic agent that can be used to ameliorate at least one symptom selected from the group consisting of: eye discharge, dull and heavy feeling, eyestrain, blurred vision, red eyes, photophobia, and itchy eyes. Provided is an ophthalmic agent containing (A) hydroxypropyl methylcellulose and (B) vitamin E.

Description

technical field [0001] The present invention relates to ophthalmic preparations and ophthalmic medicines. Background technique [0002] Eye gum (also called "eye mucus") is caused by inflammation of the conjunctiva and hypersecretion of mucous substances (mucin) on the ocular surface. Exudate, the source of ocular gum, emerges from dilated conjunctival vessels and passes through the conjunctival epithelium to the ocular surface. The substance in which mucus substance (mucin) and epithelial cells are mixed is eye gum. Mucin is secreted by conjunctival goblet cells, and its main function is to help tear fluid stay on the ocular surface, and at the same time wrap foreign bodies and bacteria from the outside world to activate the defense mechanism. The secretion of mucin from goblet cells is controlled by the parasympathetic nerves and is stimulated by stimulation of the ocular surface. Even usually, there are cases where eye gum appears on the surface of the eye, especially ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/355A61K31/07A61K31/375A61K47/38A61P27/02A61P27/04A61P27/14
CPCA61K31/07A61K31/355A61K31/375A61K47/38A61P27/02A61P27/04A61P27/14
Inventor 渡部草太田渊照人
Owner LION CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com